Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma

Table 4 Analysis of overall survival and survival after sorafenib treatment or time to treatment failure of sorafenib treatment

	n	OS ^a and survival after sorafenib treatment		OS ^a and time to treatment failure of sorafenib treatment
	n	R	P value*	r	P value*
All patients
	63	0.949	<0.001	0.508	<0.001
Child-Pugh class (Child-Pugh score)
A (5)	14	0.992	<0.001	0.176	0.56
A (6)	21	0.944	<0.001	0.687	<0.001
B	28	0.920	<0.001	0.570	0.001
BCLC stage
B	16	0.968	<0.001	0.313	0.24
C	47	0.940	<0.001	0.555	<0.001
AFP ^b, ng/mL
≥400	25	0.947	<0.001	0.490	0.012
<400	38	0.948	<0.001	0.500	0.001
Cause of failure of sorafenib treatment
Tumor progression	49	0.939	<0.001	0.596	<0.001
Adverse effect	14	0.989	<0.001	0.363	0.21
Subsequent therapy
No	13	0.880	<0.001	0.428	0.15
Any	50	0.947	<0.001	0.471	<0.001

ISSN: 1471-2407